New Pharmacological (new + pharmacological)

Distribution by Scientific Domains

Terms modified by New Pharmacological

  • new pharmacological agent
  • new pharmacological target

  • Selected Abstracts


    Management of borderline personality disorder: emerging, new pharmacological and non-pharmacological strategies

    ACTA PSYCHIATRICA SCANDINAVICA, Issue 1 2009
    Shailendra Kapoor MD
    No abstract is available for this article. [source]


    Circadian rhythm disturbances in depression,

    HUMAN PSYCHOPHARMACOLOGY: CLINICAL AND EXPERIMENTAL, Issue 7 2008
    Anne Germain
    Abstract Objective The aim of this article is to review progress in understanding the mechanisms that underlie circadian and sleep rhythms, and their role in the pathogenesis and treatment of depression. Methods Literature was selected principally by Medline searches, and additional reports were identified based on ongoing research activities in the authors' laboratory. Results Many physiological processes show circadian rhythms of activity. Sleep and waking are the most obvious circadian rhythms in mammals. There is considerable evidence that circadian and sleep disturbances are important in the pathophysiology of mood disorders. Depressed patients often show altered circadian rhythms, sleep disturbances, and diurnal mood variation. Chronotherapies, including bright light exposure, sleep deprivation, and social rhythm therapies, may be useful adjuncts in non-seasonal and seasonal depression. Antidepressant drugs have marked effects on circadian processes and sleep. Conclusions Recent progress in understanding chronobiological and sleep regulation mechanisms may provide novel insights and avenues into the development of new pharmacological and behavioral treatment strategies for mood disorders. Copyright © 2008 John Wiley & Sons, Ltd. [source]


    Program: Twenty Fourth Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders

    MOVEMENT DISORDERS, Issue 6 2010
    Article first published online: 26 APR 2010
    The symposium will consist of current issues in genetic and environmental contributions to Parkinson's disease and other movement disorders with peer-reviewed platform and poster presentations designed to communicate recent research advances, including new pharmacological and non-pharmacological treatment options, in the field of Parkinson's disease, Huntington's disease, ataxia, dystonia, myoclonus, Tourette's syndrome, tremor and other movement disorders thereby enhancing patient care. [source]


    Program: Twenty Third Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders

    MOVEMENT DISORDERS, Issue 12 2009
    Article first published online: 11 SEP 200
    The symposium will consist of two keynote speakers and peer-reviewed platform and poster presentations designed to communicate recent research advances, including new pharmacological and non-pharmacological treatment options, in the field of Parkinson's disease, Huntington disease, ataxia, dystonia, myoclonus, Tourette's syndrome, Essential Tremor and other movement disorders thereby enhancing patient care. Professionals in neurology and related disciplines as well as practitioners, psychologists, educators, and researchers are invited to attend. The gaps in clinical practice we wish to address are the unmet needs pertaining to the translational and clinical evaluation, along with the care and treatment of patients and families affected by Parkinson's disease and other movement disorders. At the conclusion of this session, participants should be able to: 1) Identify and describe by scholarly review, oral presentation and group discussion the current research into the diagnosis, prevention and treatment of Parkinson's disease (PD) and Essential Tremor (ET) which may be relevant to current treatment or which may lead to the development of further research protocols; 2) Distinguish and assess the important advances in research and clinical treatments relating to Parkinson's disease and Essential Tremor in terms of available treatment options or new methodologies for clinical research; 3) Explain new pharmacological and non-pharmacological treatment options available for Parkinson's disease and other movement disorders in connection with their clinical practice or with regard to further clinical research methods; 4) Interpret the mechanisms (genetic, environmental, pathophysiology, neurobiology) linked to Parkinson's disease and other movement disorders when assessing Parkinson's disease or other movement disorder patients or when developing new research protocols; and 5) Employ diagnostic approaches and tools available for assessing Parkinson's disease and Essential Tremor when diagnosing new patients or when conducting clinical research. [source]